Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Report 2026

The pharmaceutical contract development and manufacturing organization (cmo) market size has grown rapidly in recent years. It will grow from $54.73 billion in 2025 to $60.7 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increasing r&d expenditures by pharmaceutical companies, rising prevalence of chronic diseases, growth in generic drug demand, technological advancements in drug manufacturing, increasing focus on preclinical and clinical research.

The pharmaceutical contract development and manufacturing organization (cmo) market size is expected to see rapid growth in the next few years. It will grow to $90.76 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to rising adoption of personalized medicine, growing demand for biologics and complex therapeutics, expansion of cdmo capabilities in emerging markets, integration of digital technologies in drug development, increasing strategic partnerships and mergers in pharmaceutical sector. Major trends in the forecast period include outsourcing of drug development and manufacturing, expansion of cdmo service portfolios, regulatory compliance and quality assurance focus, strategic partnerships between pharma companies and cdmos, adoption of advanced analytical and testing services.

The increasing rate of patent expirations is expected to drive growth in the pharmaceutical contract development and manufacturing (CDMO) market. Patent expiration marks the end of the legally protected exclusive rights granted to an inventor or patent holder, allowing competitors to produce and sell generic versions of the original product. CDMOs play a critical role in enabling the rapid development and manufacturing of generic drugs to enter the market following patent expiry. For instance, in February 2024, according to DrugTimes, a China-based pharmaceutical and biotech industry analytics firm, over 25 products are projected to lose patent protection by 2037, potentially resulting in a combined revenue decline exceeding $236.4 billion based on 2024 sales. Therefore, the rising incidence of patent expirations is fueling demand for CDMO services.

Key companies in the pharmaceutical CDMO market are expanding their service offerings to meet evolving industry needs, such as through the development of integrated solutions like the DevPack. The DevPack is a service optimized across multiple partners to create a standardized dataset of development process steps, facilitating streamlined research and manufacturing. For instance, in May 2023, ASM Research Chemicals, a Germany-based provider of contract research and manufacturing services, launched DevPack, a development pack service tailored for active pharmaceutical ingredient (API) manufacturing. Optimized across ten core partners, DevPack provides a standardized dataset for development processes, supporting analytical development, regulatory submissions, and early-stage manufacturing route development for APIs. This service is particularly beneficial for CMOs and pharmaceutical companies aiming for accelerated API development.

In December 2023, Ajinomoto Group, a Japan-based global food and biotechnology company, acquired Forge Biologics Inc. for an undisclosed amount. Through this acquisition, Ajinomoto Group aims to expand its gene therapy CDMO capabilities, strengthen its global biopharmaceutical manufacturing footprint, and enhance its portfolio in advanced therapeutics. Forge Biologics Inc., a US-based CDMO, specializes in AAV-based gene therapy solutions.

Major companies operating in the pharmaceutical contract development and manufacturing organization (cmo) market are Lonza Group, Catalent Inc, WuXi AppTec Inc., Recipharm AB, Almac Group, Aenova Group, Baxter International Inc, SGS Life Science Services SA, Jubilant Pharmova Ltd, Dishman Pharmaceuticals, Kemwell Pvt. Ltd., Nipro Corp., CMIC Group, Sawai Pharmaceutical Co. Ltd, IDT Australia Limited, Aurigene Pharmaceutical Services Limited, Vetter Pharma International GMBH, Consort Medical PLC, Siegfried Holding AG, Evonik Industries, NextPharma, Royal DSM N.V, HAUPT Pharma AG, Famar, OTC-PharmNEUCA, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, TZMO, Eurofarma Laboratórios S.A., Ache Laboratórios Farmacêuticos S.A., Blanver Farmoquímica e Farmacêutica S.A., Prati-Donaduzzi, União Química Farmacêutica Nacional S.A, Laboratorios Richmond S.A.C.I.F., Bago S.A., Elea Laboratories S.A.C.I. y F., Gador S.A., LIFEPharma, Neopharm, Gulf Pharmaceutical Industries JULPHA, NewBridge Pharmaceuticals Limited, Aspen Pharmacare Holdings Limited, Adcock Ingram Holdings Limited, Pharma-Q (Pty) Ltd, Vital Health Foods, EIPICO (Egyptian International Pharmaceutical Industries Company), Pharco Pharmaceuticals.

North America was the largest region in the global pharmaceutical contract development and manufacturing market in 2025. The Middle East is expected to be the fastest-growing region in the global pharmaceutical contract development and manufacturing market during the forecast period. The regions covered in the pharmaceutical contract development and manufacturing organization (cmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical contract development and manufacturing organization (cmo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pharmaceutical contract development and manufacturing market by increasing the cost of imported raw materials, active pharmaceutical ingredients (APIs), and specialized equipment, which has raised overall production costs. This impact is most pronounced in segments such as API manufacturing and formulation development, particularly in regions like Asia-Pacific and Europe that serve as key suppliers. While tariffs have posed challenges by slowing project timelines, they have also encouraged local sourcing, regional manufacturing investments, and innovation in cost-efficient production processes, ultimately creating strategic opportunities for CDMOs to optimize supply chains.

The pharmaceutical contract development and manufacturing organization (cmo) market research report is one of a series of new reports that provides pharmaceutical contract development and manufacturing organization (cmo) market statistics, including pharmaceutical contract development and manufacturing organization (cmo) industry global market size, regional shares, competitors with a pharmaceutical contract development and manufacturing organization (cmo) market share, detailed pharmaceutical contract development and manufacturing organization (cmo) market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical contract development and manufacturing organization (cmo) industry. This pharmaceutical contract development and manufacturing organization (cmo) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical contract development and manufacturing refers to businesses that provide drug research and production services within the pharmaceutical industry. By partnering with CDMOs, pharmaceutical companies can outsource the development and manufacturing of medications. Full-service CDMOs manage all stages of the process or collaborate with clients who wish to outsource specific steps, depending on each client’s requirements.

The main types of pharmaceutical contract development and manufacturing organizations (CMOs) are contract manufacturing services and contract research services. Contract manufacturing services involve outsourcing production processes to a third-party company, known as a contract manufacturer. Research phases covered include preclinical, Phase I, Phase II, Phase III, and Phase IV. The end-use sectors include large pharmaceutical companies, generic pharmaceutical companies, and small to medium-sized pharmaceutical companies.

The pharmaceutical contract development and manufacturing market includes revenues earned by entities by providing drug development and manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.